As a new investor I am at a loss to know why this little gem never goes anywhere

Is is a medical company with no debt, a profit!, minimal market capital and some interesting products.

We're in the shares4 schools contest and we'd like this babe to fly!

Interim Results

Financial highlights
· Revenues up 28.4% to £3.88m (H1 2012: £3.02m)
· Gross margins in core MIS business increased to 45.5% (H1 2012: 44.8%)
· EBITDA up 16.8% to £1.14m (H1 2012: £976,000*)
· Operating profit* up 18.2% to £623,000 (H1 2012: £527,000*)
· Pre-tax profit* up 19.4% to £567,000 (H1 2012: £475,000*)
· Reported pre-tax profit more than tripled to £567,000 (H1 2012: £181,000)
· Adjusted basic earnings per share of 0.12p (H1 2012: 0.09p)
· Net cash of £808,000 generated from operating activities (H1 2011: £888,000*)
*comparative adjusted to exclude H1 2012 exceptional costs of £294,000

Operational highlights
· Revenues from SI branded products up 37.7% to £2.93m (H1 2012: £2.13m)
· Revenues from OEM products down 5.2% to £0.85m (H1 2012: £0.89m)
· Strong sales of Resposable® instruments with continued disposable pull through to follow
· Revenues from SI branded disposable elements up 22.8% to £1.67m (H1 2012: £1.36m)
· Impressive 144% growth in UK SI branded product revenues to £809,000 (H1 2012: £331,000)

Post-period end highlights
· Two more distributors added to growing US distribution network
· Largest ever US order, in financial terms, for SI Branded products secured in H2

Beaufort Securities Speculative Buy 6.75 6.75 - - Initiates/Starts

This doesn't seem to be going anywhere and hasn't for a long time.?
Anyone have any ideas.

Stocking order under Surgioscopy agreement

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), announces it has received and dispatched an initial stocking order from Surgioscopy worth a total of £141,000.

Trading Update

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), provides the following trading update for the 12 months ended 31 December 2013.

Total revenues for the year ended 31 December 2013 will be £8.6m, a 13% increase against the previous year (2012: £7.6m). The Group's strategy for long term growth is the development of the SI Brand within the lucrative US market, underpinned by the appointment in May 2013 of an SI President of US Sales and Operations. The Group is therefore pleased to report a substantial increase of 75% in sales to the US of SI Branded products, through multiple new routes to market, clearly demonstrating our potential for growth and vindicating the high level of initial investment required. Overall, SI Branded product revenues have grown by 23% driven by the demand for our resposable technology.

Group profitability has been adversely affected by the combined effect of the US dollar exchange rate and more significantly the strategic investment during the second half of the year in manufacturing operations designed to streamline and improve process flows of individual product lines to enable and support the 75% growth in US revenues. As a result, the adjusted EBITDA (excluding exceptional items) for the year ended 31 December 2013 will be significantly below the reported number for the year ending December 2012 (2012: £2.9m).

The chairman has just bought 1000000 shares at 1.3p. I have bought 120000 shares which is showing as sell in the trade

After a nightmare 12 months is the good news starting to flow. At £6m market capital, a new board and established custmers will the sun soon shine?

I'd forgotten all about these.

Final results for year ended 31 December 2015

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical technology for minimally invasive surgery, reports significantly improved financial results for the year ended 31 December 2015. Revenues and margins continue to show encouraging progress, whilst significant reductions in net operating costs, working capital and net indebtedness have been achieved.

Highlights:
· Revenues up 36% to £5.47m (2014: £4.03m)
· Gross margin improvement in second half of the year (2015: 14.0%, H1: 8.4%, H2: 19.2%)
· Adjusted EBITDA of £0.24m (2014: Adjusted EBITDA loss of £0.05m)
· Inventory reduction programme well advanced (2015: £1.92m, 2014: £4.30m)
· Net cash generated from operations of £1.57m (2014: £0.69m net cash consumed)
· Net indebtedness reduced to £2.26m (2014: £3.33m)
· New Board of directors and key management team in place
· New sales channels and products coming on stream in 2016

Executive Chairman, Nigel Rogers, said:
"In a year of transition for the Company, there have been many positive changes. Relationships with our distribution partners have been strengthened and revenues have returned to growth on solid foundations. Manufacturing and operating costs have been reduced, and working capital has been brought into line with the current needs of what is now a cash generative business.

"With these changes delivered and a solid platform secured for future growth, we now have a Board and management structure intended to drive the future direction and development of the business.

"There has been further improvement in performance in the current financial year to date. Although there remain some challenges in building on the improvements delivered in 2015, we look forward with renewed confidence."

For further information please contact:

Revised Banking Facilities

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative technology for minimally invasive surgery, announces the revision of banking facilities made available by Yorkshire Bank ("the bank"). The existing term loan of approximately £1.70m has been repaid from available cash resources, and the bank has made available a Revolving Credit Facility of up to £1.30m for working capital and other purposes until 31 March 2020.

Nigel Rogers, Executive Chairman of SI Group, said: "Following the announcement yesterday concerning the conversion of Loan Notes, these changes to the financing structure are a major indicator of the successful transformation that the business has undergone over the last twelve months. The Company is now debt free, and can focus full attention on developing top line growth from additional products and sales channels, and the ongoing identification of suitable acquisition targets."